Cost-minimization analysis between intravenous iron sucrose and iron sucrose similar in hemodialysis patients

Pagès, Arnaud; Porteils, C; Labadens, Isabelle; Parmier, Matthieu; Oses, Samantha; Sémély, D; Bourdoncle, M; Seigneuric, Bruno; Bello, Arnaud Del; Juillard-Condat, Blandine

doi:10.1080/14737167.2019.1632193

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considerable cost savings to healthcare providers can be made by using IV iron treatment through its ability to reduce ESA dose [40,117,[168][169][170][171] as well as reducing the need for RBC transfusions [40,113,118,121,172].…”

Section: Cost-effectiveness Of Iron Sucrosementioning

confidence: 99%

“…In a sequential observational study, switching from iron sucrose to an iron sucrose similar led to an increase in total anemia drug costs [157,173]. Additionally, in a recent cost-minimization analysis in hemodialysis patients, iron sucrose and iron sucrose similars were found to have comparable efficacy; however, using an iron sucrose similar was more expensive in 67% of iterations [171]. Although lower costs were associated with iron sucrose similars, this was offset by the requirement for higher ESA doses to obtain equivalent ferritin and TSAT levels [171].…”

Section: Cost-effectiveness Of Iron Sucrosementioning

confidence: 99%

See 1 more Smart Citation

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

et al. 2020

View full text Add to dashboard Cite

Iron deficiency and iron-deficiency anemia are associated with increased morbidity and mortality in a wide range of conditions. In many patient populations, this can be treated effectively with oral iron supplementation; but in patients who are unable to take or who do not respond to oral iron therapy, intravenous iron administration is recommended. Furthermore, in certain conditions, such as end-stage kidney disease, chronic heart failure, and inflammatory bowel disease, intravenous iron administration has become first-line treatment. One of the first available intravenous iron preparations is iron sucrose (Venofer ® ), a nanomedicine that has been used clinically since 1949. Treatment with iron sucrose is particularly beneficial owing to its ability to rapidly increase hemoglobin, ferritin, and transferrin saturation levels, with an acceptable safety profile. Recently, important new data relating to the use of iron sucrose, including the findings from the landmark PIVOTAL trial in patients with end-stage kidney disease, have been reported. Several years ago, a number of iron sucrose similars became available, although there have been concerns about the clinical appropriateness of substituting the original iron sucrose with an iron sucrose similar because of differences in efficacy and safety. This is a result of the complex and unique physicochemical properties of nanomedicines such as iron sucrose, which make copying the molecule difficult and problematic. In this review, we summarize the evidence accumulated during 70 years of clinical experience with iron sucrose in terms of efficacy, safety, and cost-effectiveness.

show abstract

Section: Cost-effectiveness Of Iron Sucrosementioning

confidence: 99%

Section: Cost-effectiveness Of Iron Sucrosementioning

confidence: 99%

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

et al. 2020

View full text Add to dashboard Cite

show abstract

Tackling the challenges of nanomedicines: are we ready?

Hertig

Shah

Flühmann

et al. 2021

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

Disclaimer In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose This review provides an overview of the proceedings of the symposium “Tackling the Challenges of Nanomedicines: Are We ready?” organized by the International Pharmaceutical Federation (FIP) Hospital Pharmacy Section and Non-Biological Complex Drugs (NBCDs) Working Group at the 2019 FIP World Congress of Pharmacy and Pharmaceutical Sciences. Debate centered on reasons underlying the current complex regulatory landscape for nanomedicines and their follow-on products (referred to as nanosimilars) and the pivotal role of hospital pharmacists in selecting, handling, and guiding usage of nanomedicines and nanosimilars. Summary The evaluation and use of nanomedicines are recognized among scientific, pharmaceutical, and regulatory bodies as complex. Interchangeability and substitutability of nanomedicines and nanosimilars are confounded by a lack of pharmaceutical and pharmacological equivalence, reflecting the inherent complex nature of these drug products and manufacturing processes. Consequences include implications for clinical safety and efficacy and, ultimately, comparability. Local regulatory approvals of some nanomedicines have occurred, but there is no standard to ensure streamlined evaluation and use of consistent measures of therapeutic equivalence of reference products and their nanosimilars. Hospital pharmacists are expected to be experts in the selection, handling, and substitution of nanomedicines and familiarize themselves with the limitations of current methods of assessing pharmaceutical and clinical equivalence of nanosimilars in order to ensure informed formulary decision-making and eventual patient benefit. Conclusion Supportive guidance for pharmacists focusing on the substitutability and/or interchangeability of nanomedicines and their nanosimilars is needed. Current FIP guidance for pharmacists on therapeutic interchange and substitution should be extended to include nanomedicines and nanosimilars.

show abstract

Cost-minimization analysis between intravenous iron sucrose and iron sucrose similar in hemodialysis patients

Cited by 2 publications

References 16 publications

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

Tackling the challenges of nanomedicines: are we ready?

Contact Info

Product

Resources

About